Tag Archives: Mirati Therapeutics

Cowen & Co. Believes Mirati Therapeutics (NASDAQ: MRTX) Won’t Stop Here

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) today. The company’s shares closed yesterday at $89.20, close to its 52-week high of $96.70. According to TipRanks.com, Shibutani is a 3-star analyst

Analysts Offer Insights on Healthcare Companies: Mirati Therapeutics (NASDAQ: MRTX) and Spectrum Pharmaceuticals (NASDAQ: SPPI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mirati Therapeutics (MRTX – Research Report) and Spectrum Pharmaceuticals (SPPI – Research Report). Mirati Therapeutics (MRTX) In a report released yesterday, Varun Kumar

Cowen & Co. Reaffirms Their Buy Rating on Mirati Therapeutics (MRTX)

In a report released today, Chris Shibutani from Cowen & Co. reiterated a Buy rating on Mirati Therapeutics (MRTX – Research Report). The company’s shares closed yesterday at $67.18. According to TipRanks.com, Shibutani is a 3-star analyst with an average

Cantor Fitzgerald Reiterates Their Hold Rating on Mirati Therapeutics (MRTX)

Cantor Fitzgerald analyst Varun Kumar reiterated a Hold rating on Mirati Therapeutics (MRTX – Research Report) yesterday and set a price target of $66. The company’s shares closed yesterday at $59.49. Kumar noted: “: We reiterate our Neutral rating and

Cowen & Co. Believes Mirati Therapeutics (NASDAQ: MRTX) Still Has Room to Grow

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report). The company’s shares opened today at $72.53, close to its 52-week high of $79.31. According to TipRanks.com, Shibutani

Mirati Therapeutics (MRTX) Receives a Hold from Cantor Fitzgerald

Mirati Therapeutics (MRTX – Research Report) received a Hold rating and a $66 price target from Cantor Fitzgerald analyst Varun Kumar today. The company’s shares opened today at $72.37, close to its 52-week high of $79.31. Kumar observed: “: We